Aims: Type 2 diabetes is a major health problem placing increasing demands on healthcare systems. Our objective was to estimate healthcare resource use and related financial costs following treatment with exenatide-based regimens prescribed as once-weekly (EQW) or twice-daily (EBID) formulations, compared with regimens based on basal insulin (BI). Conclusion: Overall, exenatide once-weekly and twice-daily-based regimens were associated with reduced healthcare resource use and costs compared with basal-insulin-based regimens.
insulin analogues [3] [4] [5] [6] [7] [8] [9] [10] and is associated with weight reductions. 3 In addition to the immediate-release formulation to be used twice a day, exenatide is also available as an extended-release formulation, thereby offering the advantage of a simpler dosing regimen.
In the CHOICE (CHanges to Treatment and Outcomes in Patients
With Type 2 Diabetes Initiating InjeCtablE Therapy) observational study based in 6 European countries, total healthcare costs were higher over a 24-month period in those receiving twice-daily exenatide when compared with those receiving insulin (€3998 vs €3267).
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However, following exclusion of the cost attributed to insulin or twice-daily exenatide, the cost of other healthcare resource utilization was lower for exenatide (€1792 vs €2466).
In addition to clinical factors, cost can be an important consideration when selecting the most appropriate glucose-lowering therapy to initiate in patients with type 2 diabetes. 2 In this retrospective, observational cohort study, we aim to estimate, using UK primary and secondary care data, NHS resource use and related costs in patients who are receiving regimens that include exenatide in its once-weekly (EQW) or twice-daily formulation (EBID), compared with regimens including basal insulin (BI). To our knowledge, this is the first study to compare the use and cost of NHS healthcare resources in patients treated with exenatide and insulin.
| MATERIALS AND METHODS

| Data sources
Retrospective data were extracted from the UK Clinical Practice
Research Datalink (CPRD). CPRD is a proprietary healthcare data resource containing clinically rich, pseudonymized data on 14 million research-quality patients registered at 689 UK primary care practices, of which 4.9 million patients are actively registered (representing approximately 7% of the UK population). These data are collected in a non-interventional manner and include patient demographics, consultations, medical history, test results and prescriptions. Patients registered in CPRD are broadly representative of the UK population in terms of age and gender. 12 The geographical distribution of patients and practices in CPRD has been described previously. 12 Briefly, the percentage of acceptable patients registered in CPRD by region varies between 3.9% from Yorkshire and the Humber to 
| Patients
| Prescriptions
Prescriptions for glucose-lowering therapies (including glucoselowering therapies other than BI or exenatide prescribed concomitantly), injection equipment (needles and syringes), equipment used for self-monitoring of blood glucose (strips and lancets), drugs used for treatment of obesity, antihypertensives, antiplatelets and lipidlowering therapies were identified in CPRD. Each prescription was matched to the corresponding product listed in the Prescription Cost Analysis (PCA) report for 2014 15 and attributed a net ingredient cost (NIC) per quantity. The NIC refers to the cost of the drug before discounts and does not include any dispensing costs or fees. 15 For those products that were discontinued before 2014 and therefore not included in the 2014 PCA, the NIC per quantity listed in the most recent prior version of the PCA was used and the cost was inflated to 2014 prices using the Gross Domestic Product Deflator from Her Majesty's Treasury. 16 The quantity of medication entered in each of the relevant prescriptions was determined and its unit converted, if necessary, to the Standard Quantity Unit used for the corresponding product in the PCA. This quantity was then multiplied by the NIC per quantity in order to determine the cost of each prescription.
| Secondary care resource use
Data from inpatient admissions recorded in HES were processed into Healthcare Resource Groups (HRGs) using HRG-4 grouper. The allocated HRGs were linked to the 2013 to 2014 National Tariff, 17 adjusting for the nature of admission (elective vs emergency) and excess length of stay.
| Statistical analysis
Continuous baseline characteristics were compared using the independent t-test or Mann-Whitney U test, depending on distribution.
Categorical variables were compared using the chi-squared test. Frequency and cost of primary care contacts and inpatient admissions were compared, using adjusted annual cost ratios (aACR). 
| Sensitivity analysis
As a sensitivity analysis, patients were required to have been registered at their GP practice for at least 90 days before the index date in order to identify incident therapies.
Additional sensitivity analyses were performed based on cohorts matched by propensity score. The following baseline criteria were used to generate the propensity score: age at index date, gender, BMI, dura- 
| Baseline characteristics
Patients receiving BI were older than those receiving EQW (mean age, 64.8 vs 55.7 years, P < .001) and EBID (mean age, 64.8 vs 56.6 years, P < .001), with a longer duration of diagnosed diabetes (median, 9.1 years for BI; 8.0 years, P < .005, for EQW; 7.4 years, P < .001, for EBID, Table 1 ). HbA1c at baseline was higher for patients receiving BI in comparison with those receiving EQW (9.7% vs 9.3%, P < .001) and EBID (9.7% vs 9.2%, P < .001). More patients receiving BI had a history of major adverse cardiac events and cancer as compared with those receiving EQW (19% vs 9%, P < .001, for major adverse cardiac events and 14% vs 6%, P = .001, for cancer)
and EBID (19% vs 9%, P < .001, for major adverse cardiac events and 14% vs 6%, P < .001, for cancer). Patients receiving BI also had a Fewer patients receiving BI had received prescriptions for lipidlowering therapy when compared with those receiving EQW (72% vs 78%, P = .037) and EBID (72% vs 85%, P < .001), and fewer patients receiving BI had received prescriptions for antihypertensive therapy when compared with those receiving EBID (70% vs 79%, P < .001).
There were no missing data for any of the characteristics used to generate the propensity score in 5987 patients receiving BI, in 193 patients receiving EQW and in 1913 patients receiving EB. A total of 188 patients receiving BI were successfully matched to 188 patients receiving EQW, and 1486 patients receiving BI were matched to 1486 patients receiving EBID. Following propensity-score matching, more patients receiving EQW had previously been receiving lipid-lowering therapy compared with those receiving BI (79% vs 69%, P = .019).
Duration of diagnosed diabetes was longer for those receiving EBID than for those receiving BI (median, 7.8 vs 7.4 years, P = .018). Diastolic blood pressure (78.8 vs 78.1 mm Hg, P = .039) and BMI (36.9 vs 36.1 kg/m 2 , P < .001) were also higher in those receiving EBID.
A sensitivity analysis was carried out, using patients with a minimum wash-in of 90 days between the patient's current registration date with their GP practice and the study index date. Baseline characteristics of these patients are detailed online in Table S1 .
| Healthcare resource use
Overall, the cost of glucose-lowering therapies was higher in patients receiving EQW than in those receiving BI (£914 vs £507
per patient-year (ppy), aACR, 1.55; 95% CI, 1.55-1.56) (Table 2A) .
Following propensity-score matching, this difference remained (£926 Table 2B .
In the sensitivity analysis, selecting only those patients with a wash-in of ≥90 days between current registration date and index date, patients receiving EQW had lower overall costs compared with those allocated to the BI cohort (£2809 vs £3857 ppy; aACR, 0.99, 95% CI, 0.99-0.99) and in the subgroup matched by propensity score (£2782 vs £3616 ppy; aACR, 0.92; 95% CI, 0.91-0.92) (Table S2A ).
Patients receiving EBID had lower total costs when compared with those treated with BI in the overall analysis (£2534 vs £3857 ppy; b Nearest record to the index date, providing it was no more than 365 days before or 30 days after the index date. The search was conducted in the following order: −30, +30 and −365 days. 
aACR, 0.86; 95% CI, 0.86-0.86) and following propensity-score matching (£2543 vs £3032 ppy; aACR, 0.82, 95% CI, 0.82-0.82) (Table S2B ).
| DISCUSSION
Compared with patients treated with BI, patients treated with exenatide in its once-weekly (EQW) and twice-daily (EBID) formulations had significantly lower rates of primary care contacts and inpatient admissions and, consequently, engendered lower total financial costs in spite of exenatide's higher pharmacy cost. Lower total costs for patients treated with EQW or EBID were also observed in the propensity-score-matched analysis. However, total costs were lower in the subgroup of BI patients matched by propensity score than in the original BI cohort. This is probably related to the decrease in mean age of patients receiving BI following propensity-score matching, where age is related to increased disease severity, increased morbidity and patient frailty.
In several studies, exenatide has been reported to have numerous clinical benefits when compared with insulin. In a meta-analysis by Wang and colleagues, GLP-1 receptor agonists were associated with greater reductions in HbA1c and weight, which may help to mitigate cardiovascular risk, in comparison with insulin. 19 Furthermore, in randomized trials, EQW has been reported to provide improved glycaemic control compared with EBID. 20, 21 In a retrospective study, exenatide was associated with a reduced cardiovascular risk compared with insulin.
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It is important for patented products such as exenatide to demonstrate not only efficacy but also cost-effectiveness. In this study, despite higher drug costs, overall costs were lower in the exenatide cohorts than in the BI cohort, largely explained by fewer primary care contacts and fewer hospital admissions. Several studies have investigated the cost-effectiveness of exenatide vs insulin. In a systematic review and economic evaluation carried out by Waugh and colleagues, the cost-effectiveness of EBID vs insulin glargine was estimated at approximately £20 000 per quality-adjusted life years (QALY), decreasing to £1600 per QALY in patients with a BMI of 35 kg/m 2 .
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Insulin dose increases with weight, whereas exenatide is prescribed as a fixed dose and, indeed, the authors reported an improvement in the cost of EBID relative to insulin glargine as BMI increased. 23 A further small benefit of EBID in terms of QALY was reported to be related to its association with weight loss. 23 Several other studies have investigated the cost-effectiveness of EBID vs insulin glargine and EBID was shown to be cost-effective in Germany, 24 Switzerland 25 and the UK. 26 For EQW, the cost per QALY gained when com- . 27 However, as the study was conducted prior to the launch of EQW, the price was derived from GLP-1 receptor agonists already on the market. 27 When compared with insulin glargine, EQW Other diabetes-related products comprised injection equipment (needles and syringes) and appliances used for self-monitoring of blood glucose (strips and lancets).
has also been reported to be cost-effective in the USA ($15 936 per QALY) and for patients with BMI of >30 kg/m 2 in Spain (ICER, €12 084 per QALY gained). 28 In the CHOICE study, total healthcare costs over a 24-month period post-initiation of study drugs were higher in those receiving EBID than in those receiving insulin (€3997.9 vs €3265. 
| Limitations
In this study, we were able to investigate healthcare resource utilization in real-world clinical practice. However, this study had a number of inherent limitations that are associated with retrospective observational studies. Patients were not randomized to each treatment cohort, and patient characteristics that were not known or could not be fully accounted for may have driven the decision to prescribe a particular therapy. We have aimed to reduce this risk of bias through the use of multivariate models and propensityscore matching. However, it is possible that confounding by indication and residual confounding from factors that are difficult to measure or quantify in retrospective data, such as diabetes severity and patient frailty, may exist. The purpose of the propensity matching process was to equalize the difference in baseline characteristics. However, it should be considered that those BI patients who were included in the propensity-score-matched cohort are probably atypical of the cohort as a whole. This may affect the generalizability of results.
As with other routine data, the data sources for this study probably involve coding imperfections, misclassifications or omission of diagnoses. It is also probable that data were not missing at random but reflected patient characteristics. For 27% of patients, there were missing data for 1 or more of the characteristics used to generate the propensity score and these were, therefore, excluded from the matching process. Missing data were more common in those treated with BI (32% vs 21% for EQW and 32% vs 22% for EBID). Missing data also could have affected study outcomes. The HES inpatient dataset does not contain information on private treatments. As prescriptions are generated electronically, we expect that the completeness of data was relatively high for prescriptions issued in primary care. However, prescriptions issued in secondary care are unlikely to be recorded in CPRD. Although this is difficult to quantify, we have no reason to suspect any issue of missing data in the recording of primary care consultations or secondary care inpatient admissions.
Should data be missing, however, this is unlikely to affect 1 treatment cohort more than another.
Some assumptions were required when applying costs to healthcare resource use. Costs were applied only to consultations involving verbal contact with the patient (face-to-face or via telephone). As discontinued medicines are no longer listed in the Prescription Cost Analysis for England 2014, the most recently recorded costs from earlier Prescription Cost Analyses were used and inflated.
Exposure to study therapy was based on a record of 1 or more prescriptions in CPRD. However, we were not able to determine whether this prescription was filled at the pharmacy or taken by the patient. Adherence to the prescribed medicine also may have differed between study cohorts. Misclassification of drug exposure was possible. However, a consistent approach was maintained throughout selection of the therapies of interest.
Baseline characteristics were derived using data recorded prior to index date. For those with a short or no registration period prior to index date, we needed to rely on the recording of prior and current medical conditions and monitoring information at registration.
For BMI, HbA1c, total cholesterol, blood pressure and serum creatinine, the nearest recorded result to index date was selected, where records were searched in the following order: 30 days prior to index, 30 days post-index and 365 days prior to index date. Use of data up to 365 days prior was considered appropriate in order to reduce the percentage of missing data.
In conclusion, type 2 diabetes places an increasing burden on the NHS. In this study we have shown that treatment with EQW and EBID was associated with reduced healthcare resource use and costs compared with BI-based regimens. Although the analysis adjusted for key baseline characteristics, the possibility of residual and unmeasured confounding should be considered when interpreting results.
